Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study.

PubWeight™: 1.01‹?› | Rank: Top 15%

🔗 View Article (PMC 3104294)

Published in Int J Geriatr Psychiatry on July 01, 2008

Authors

Gregory H Pelton1, Oliver L Harper, Matthias H Tabert, Harold A Sackeim, Nikolaos Scarmeas, Steven P Roose, D P Devanand

Author Affiliations

1: Late Life Depression Clinic, The Memory Disorders Center, and The Division of Geriatric Psychiatry, New York State Psychiatric Institute, NY, USA. ghp4@columbia.edu

Associated clinical trials:

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment | NCT01876823

Articles citing this

Depression and risk of developing dementia. Nat Rev Neurol (2011) 2.31

Treatment for mild cognitive impairment: systematic review. Br J Psychiatry (2013) 1.58

Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry (2011) 1.48

Neurocognitive correlates of response to treatment in late-life depression. Am J Geriatr Psychiatry (2008) 1.15

A new strategy for antidepressant prescription. Front Neurosci (2010) 0.96

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother (2009) 0.93

Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. Contemp Clin Trials (2013) 0.80

The nuances of cognition and depression in older adults: the need for a comprehensive assessment. Int J Geriatr Psychiatry (2013) 0.78

Impact of pharmacological and psychological treatment methods of depressive and anxiety disorders on cognitive functioning. J Neural Transm (Vienna) (2014) 0.76

Olfactory Deficits Predict Cognitive Improvement on Donepezil in Patients With Depression and Cognitive Impairment: A Randomized Controlled Pilot Study. Alzheimer Dis Assoc Disord (2016) 0.75

Depressive Symptoms in Clinical and Incipient Alzheimer's Disease. Neurodegener Dis Manag (2013) 0.75

Computerized Cognitive Training for Major Depressive Disorder: What's Next? Front Psychiatry (2015) 0.75

Articles cited by this

Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09

Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04

Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry (2006) 3.44

Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology (2002) 3.40

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 2.99

Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry (1996) 2.99

Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry (2003) 2.70

Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study. Arch Gen Psychiatry (1999) 2.45

The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord (1999) 2.30

Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull (1995) 2.26

The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry (1993) 1.92

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology (2004) 1.91

Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. Psychol Med (1996) 1.84

Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry (1995) 1.67

Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain (2004) 1.44

MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology (1996) 1.42

Neuropsychological differences between late-onset and recurrent geriatric major depression. Am J Psychiatry (2005) 1.41

Serotonin and human cognitive performance. Curr Pharm Des (2006) 1.11

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry (2002) 1.08

Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: is there a relationship? Am J Geriatr Psychiatry (2004) 1.02

Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry (2003) 1.01

Frontostriatal deficits in unipolar major depression. Brain Res Bull (1998) 0.99

A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry (2007) 0.91

Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging (2006) 0.91

Cognitive functioning in a mildly to moderately depressed geriatric sample: relationship to chronological age. J Neuropsychiatry Clin Neurosci (1994) 0.89

Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci (2006) 0.87

Treatment of vascular dementia and vascular cognitive impairment. Neurologist (2007) 0.83

Six-month outcomes for MRI-related vascular depression. Depress Anxiety (1998) 0.81

Mild cognitive impairment: where are we? Alzheimer Dis Assoc Disord (2005) 0.80

Greater depression severity associated with less improvement in depression-associated cognitive deficits in older subjects. Am J Geriatr Psychiatry (2002) 0.80

Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies. J Am Geriatr Soc (1985) 0.79

Age of onset and medical illness in older depressed inpatients. Int Psychogeriatr (1995) 0.79

Quantitative and qualitative differences in the verbal learning performance of elderly depressives and healthy controls. J Int Neuropsychol Soc (1998) 0.78

Articles by these authors

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64

Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry (2007) 5.59

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05

Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81

Physical properties and quantification of the ECT stimulus: I. Basic principles. Convuls Ther (1994) 4.18

Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA (2009) 4.01

Food combination and Alzheimer disease risk: a protective diet. Arch Neurol (2010) 3.99

Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry (2004) 3.84

Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80

Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul (2008) 3.50

Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med (1993) 3.45

Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry (2006) 3.44

Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry (2010) 3.14

A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry (2000) 3.06

Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry (1993) 2.80

Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology (2002) 2.79

Parietal cortex and representation of the mental Self. Proc Natl Acad Sci U S A (2004) 2.73

Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry (2003) 2.70

Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann Neurol (2013) 2.68

Brain networks associated with cognitive reserve in healthy young and old adults. Cereb Cortex (2005) 2.37

Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology (2008) 2.31

Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 2.24

Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry (2004) 2.24

Response inhibition predicts poor antidepressant treatment response in very old depressed patients. Am J Geriatr Psychiatry (2007) 2.18

Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci (2007) 2.12

Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol (2003) 2.08

Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry (2002) 1.95

Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry (2008) 1.93

Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol (2008) 1.92

The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry (2000) 1.91

Mediterranean-style diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study. Am J Clin Nutr (2011) 1.91

Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry (2005) 1.90

Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry (2006) 1.90

Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol (2009) 1.86

An event-related fMRI study of the neurobehavioral impact of sleep deprivation on performance of a delayed-match-to-sample task. Brain Res Cogn Brain Res (2004) 1.80

Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom (2009) 1.79

A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput (2005) 1.78

Functional significance of mild cognitive impairment in elderly patients without a dementia diagnosis. Am J Geriatr Psychiatry (1999) 1.77

Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry (2007) 1.76

An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol (2006) 1.73

The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol (1990) 1.71

Vascular depression: A distinct diagnostic subtype? Biol Psychiatry (2006) 1.66

Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT (2013) 1.62

A quality-based review of randomized controlled trials of psychodynamic psychotherapy. Am J Psychiatry (2010) 1.62

Cognitive reserve modulates functional brain responses during memory tasks: a PET study in healthy young and elderly subjects. Neuroimage (2003) 1.62

Treatment of the modal patient: does one size fit nearly all? J ECT (2001) 1.61

Absence of histological lesions in primate models of ECT and magnetic seizure therapy. Am J Psychiatry (2004) 1.60

Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder. Am J Psychiatry (2004) 1.59

Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry (2005) 1.57

Who responds to electroconvulsive therapy? A comparison of effective and ineffective forms of treatment. Br J Psychiatry (1996) 1.56

The effects of electroconvulsive therapy on quantitative electroencephalograms. Relationship to clinical outcome. Arch Gen Psychiatry (1996) 1.53

Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology (1994) 1.53

Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol (2002) 1.51

Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry (2011) 1.50

Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab (2007) 1.50

Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage (2004) 1.49

A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry (2005) 1.48

Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol (2008) 1.48

A model of placebo response in antidepressant clinical trials. Am J Psychiatry (2013) 1.46

Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One (2011) 1.45

Regional cerebral blood flow in mood disorders. II. Comparison of major depression and Alzheimer's disease. J Nucl Med (1993) 1.45

Quantitative EEG during seizures induced by electroconvulsive therapy: relations to treatment modality and clinical features. I. Global analyses. J ECT (2000) 1.44

An event-related fMRI study of the neural networks underlying the encoding, maintenance, and retrieval phase in a delayed-match-to-sample task. Brain Res Cogn Brain Res (2004) 1.44

A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol (2005) 1.42

Does ECT permanently alter seizure threshold? Biol Psychiatry (1993) 1.41

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol (2005) 1.39

Prolactin response to electroconvulsive therapy: effects of electrode placement and stimulus dosage. Biol Psychiatry (1998) 1.38

Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res (2005) 1.36

Predictors of retrograde amnesia following ECT. Am J Psychiatry (1995) 1.35

Diet and Alzheimer's disease. Curr Neurol Neurosci Rep (2007) 1.35

Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res (1990) 1.32

Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement (2012) 1.31

Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology (2003) 1.30

Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatr Clin North Am (1991) 1.27

Olfactory dysfunction as a predictor of neurodegenerative disease. Curr Neurol Neurosci Rep (2006) 1.26

Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology (2002) 1.25

Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry (2009) 1.23

Quantitative approaches for assessment of white matter hyperintensities in elderly populations. Psychiatry Res (2011) 1.22

Leisure activity and cognitive decline in incident Alzheimer disease. Arch Neurol (2007) 1.21

A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry (2003) 1.21

The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol (2006) 1.20

The vascular depression subtype: evidence of internal validity. Biol Psychiatry (2008) 1.19

The effects of patient function and dependence on costs of care in Alzheimer's disease. J Am Geriatr Soc (2008) 1.19

Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression. Am J Geriatr Psychiatry (2010) 1.18

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry (2002) 1.17

Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc (2006) 1.16

Depressive symptoms in Alzheimer's disease: natural course and temporal relation to function and cognitive status. J Am Geriatr Soc (2005) 1.15

Plasma ß-amyloid and cognitive decline. Arch Neurol (2010) 1.13

CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg (2005) 1.13

Focal electrical stimulation as a sham control for repetitive transcranial magnetic stimulation: Does it truly mimic the cutaneous sensation and pain of active prefrontal repetitive transcranial magnetic stimulation? Brain Stimul (2008) 1.13

Psychopathological features in Alzheimer's disease: course and relationship with cognitive status. J Am Geriatr Soc (2003) 1.12

Olfactory identification deficits and MCI in a multi-ethnic elderly community sample. Neurobiol Aging (2008) 1.10

APOE genotype and cerebral blood flow in healthy young individuals. JAMA (2003) 1.09